Trials / Completed
CompletedNCT02345213
A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the efficacy of Aricept in patients with dementia with Lewy bodies (DLB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2020 | E2020 tablets will be orally administered once daily after breakfast |
| DRUG | Placebo | Matching placebo tablets will be orally administered once daily after breakfast |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2017-05-15
- Completion
- 2018-03-26
- First posted
- 2015-01-26
- Last updated
- 2019-01-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02345213. Inclusion in this directory is not an endorsement.